Jan Sjoberg
Overview
Explore the profile of Jan Sjoberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
580
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Claesson H, Sjoberg J, Xu D, Bjorkholm M
Prostaglandins Other Lipid Mediat
. 2024 Jul;
174:106871.
PMID: 38992854
This mini-review addresses lipoxygenases and receptors for leukotrienes in hematological malignancies. Potential novel biomarkers and drug targets in leukemia and B-cell lymphoma are discussed.
2.
Weibull C, Sjoberg J, Dickman P, Bjorkholm M
Acta Oncol
. 2023 Sep;
62(12):1942-1944.
PMID: 37708099
No abstract available.
3.
Xia C, Olsen T, Zirakzadeh A, Almamoun R, Sjoholm L, Dahlstrom J, et al.
Front Oncol
. 2020 Dec;
10:598872.
PMID: 33363029
We studied DNA methylation profiles in four different cell populations from a unique constellation of monozygotic triplets in whom two had developed Hodgkin Lymphoma (HL). We detected shared differences in...
4.
Moscetti L, Hennik P, Bolstad B, Camarero J, Josephson F, Melchiorri D, et al.
ESMO Open
. 2020 Aug;
5(4).
PMID: 32847837
The therapeutic landscape in the treatment of advanced/metastatic renal cell cancer has evolved over the last 2 years with the advent of immune checkpoint inhibitors. In 2018 and 2019, marketing...
5.
Tzogani K, Hennik P, Walsh I, De Graeff P, Folin A, Sjoberg J, et al.
Oncologist
. 2018 Jul;
23(7):870.
PMID: 30037941
No abstract available.
6.
Tzogani K, Hennik P, Walsh I, De Graeff P, Folin A, Sjoberg J, et al.
Oncologist
. 2017 Dec;
23(5):631-636.
PMID: 29192015
Implications For Practice: Farydak was approved in the European Union in combination with bortezomib and dexamethasone, for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have...
7.
Stanel S, Sjoberg J, Salmonson T, Foggi P, Caleno M, Melchiorri D, et al.
ESMO Open
. 2017 Aug;
2(2):e000190.
PMID: 28761750
On 1 February 2013, a marketing authorisation valid throughout the European Union was issued for aflibercept (Zaltrap) in combination with irinotecan/5-fluorouracil/folinic acid chemotherapy for the treatment of adults with metastatic...
8.
Han H, Liang X, Ekberg M, Kritikou J, Brunnstrom A, Pelcman B, et al.
FASEB J
. 2016 Nov;
31(2):491-504.
PMID: 27825104
Dendritic cells (DCs) involved in proinflammatory immune responses derive mainly from peripheral monocytes, and the cells subsequently mature and migrate into the inflammatory micromilieu. Here we report that suppressing of...
9.
Han H, Xue-Franzen Y, Miao X, Nagy E, Li N, Xu D, et al.
Prostaglandins Other Lipid Mediat
. 2015 Jun;
121(Pt A):122-30.
PMID: 26115646
Classical Hodgkin lymphoma (cHL) has a unique pathological feature characterized by a minority of malignant Hodgkin Reed-Sternberg (H-RS) cells surrounded by numerous inflammatory cells. Cysteinyl-leukotrienes (CysLTs) are produced by eosinophils,...
10.
Kristinsson S, Gao Y, Bjorkholm M, Lund S, Sjoberg J, Caporaso N, et al.
Int J Hematol
. 2015 Mar;
101(6):563-8.
PMID: 25758095
Patients with Hodgkin lymphoma (HL) have a well-characterized immune deficiency of T cell function, originally identified by increased susceptibility to certain infections. Epidemiological evidence has long pointed to infectious etiologies...